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With great interest, we read the article
by Villar et al., who investigated the
angiotensin-converting enzyme
insertion/deletion (ACE I/D) poly-
morphism in relationship to sepsis
and acute respiratory syndrome
(ARDS) in over 300 Spanish patients.
The authors did not ﬁnd an associa-
tion between this polymorphism and
susceptibility, and outcome in either
severe sepsis or ARDS [1]. In our
opinion, the authors’ explanation for
this lack of association is not sufﬁ-
ciently discussed and we hope to open
the discussion on this topic by raising
several issues. First, the authors cor-
rectly noted that ACE is an important
enzyme involved in cardiovascular
homeostasis [2]. We are disappointed
that the authors investigated only one
(non-functional) polymorphism in the
ACE-gene. Instead of investigating
one polymorphism, we would have
preferred analysis of common varia-
tion in the complete ACE-gene,
which would have been easy and
feasible in such a relatively small
population. This would have signiﬁ-
cantly strengthened any associations
between ACE-genotypes and sepsis.
In addition, it is good to realize that
the ACE I/D polymorphism is only
responsible for less than 20% varia-
tion of plasma ACE levels. It is hard
to believe that such a single poly-
morphism accounts for a signiﬁcant
causal effect on endpoints such as
sepsis and ARDS, which are probably
syndromes that are highly inﬂuenced
by microbial characteristics and
polygenetic factors. Second, the
authors reported a statistical power of
76–85% using a sample size of 212
septic and 120 ARDS patients. An
adequate study size and statistical
power are necessary to exclude false
negative or positive association stud-
ies. An important review article in
this ﬁeld recently addressed that a
number of 2,000 patients with sepsis
would be required to detect a mor-
tality relative risk of 1.5 from any
polymorphism [3]. Third, the authors
did not fully explain why the ACE I/
D polymorphism could be important
in sepsis, since individuals who have
the DD-genotype usually have higher
ACE levels relative to controls,
whereas in septic ARDS patients
markedly decreased plasma ACE
levels have been observed [4, 5]. In
this respect, it would have been nice
if the authors would have correlated
their ﬁndings to plasma ACE levels.
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